Hepatic arterial embolization in patients with neuroendocrine tumors

Liver metastases occur in 46-93% of patients with neuroendocrine neoplasms (NENs). Presence and extension of liver metastases are considered important prognostic factors, as they may significantly impair the patient's quality of life, because of either tumor bulk or hormonal hypersecretion. The...

Full description

Saved in:
Bibliographic Details
Published in:Journal of experimental & clinical cancer research 2014-05, Vol.33 (1), p.43-43, Article 43
Main Authors: Del Prete, Michela, Fiore, Francesco, Modica, Roberta, Marotta, Vincenzo, Marciello, Francesca, Ramundo, Valeria, Di Sarno, Antonella, Carratù, Annachiara, di Roseto, Chiara de Luca, Tafuto, Salvatore, Tatangelo, Fabiana, Baldelli, Robero, Colao, Annamaria, Faggiano, Antongiulio
Format: Article
Language:English
Subjects:
Antineoplastic Agents - administration & dosage
Cancer
Care and treatment
Chemoembolization, Therapeutic
Development and progression
Health aspects
Hepatic Artery - pathology
Humans
Liver
Liver Neoplasms - mortality
Liver Neoplasms - secondary
Liver Neoplasms - therapy
Metastasis
Methods
Neuroendocrine Tumors - mortality
Neuroendocrine Tumors - secondary
Neuroendocrine Tumors - therapy
Prognosis
Review
Survival Rate
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Liver metastases occur in 46-93% of patients with neuroendocrine neoplasms (NENs). Presence and extension of liver metastases are considered important prognostic factors, as they may significantly impair the patient's quality of life, because of either tumor bulk or hormonal hypersecretion. Therapies for NEN liver metastases include surgical resection, liver transplantation, chemotherapy and biotherapy. Surgery is the gold standard for curative therapy, but in most of NEN patients with liver metastases, when surgery can not be applied, minimally invasive therapeutic approaches are adopted. They include trans-arterial embolization (TAE), trans-arterial chemoembolization (TACE), radiofrequency thermal ablation and new emerging techniques.TAE is based on selective infusion of particles in the branch of the hepatic artery supplying the tumor lesions. The goal of TAE is to occlude tumor blood vessels resulting in ischemia and necrosis. Many reports have shown that TAE can reduce tumor size and hormone output, resulting in palliation of symptoms without the use of cytotoxic drugs, resulting in better tolerability. This review will focus on TAE performance and safety in NEN patients with liver metastases.
ISSN:1756-9966
0392-9078
1756-9966
DOI:10.1186/1756-9966-33-43